

## **Prior Authorization Request Form for COPD Agents**

## FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720
OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

OIL	Tioi authorization may be com	neted at netpsi//	WW.COVC	i my meusico	m/ mam/ prior authorization forms		
I. PROVIDER INFORMATION			II. MEMBER INFORMATION				
Prescriber Name:			Member Name:				
Prescriber Specialty:			Identification #:				
NPI:			Group #:				
Office Contact Name:			Date of Birth:				
Fax #:			Medication Allergies:				
Phone	#:						
III. DI	RUG INFORMATION (One drug	g request per for	m)				
Drug n	name and strength:	Dosage Interval (s	ig):		Qty. per Day:		
	EQUIRED DOCUMENTION (Det must be submitted with prior of			umentation	demonstrating evidence for each		
Specify diagnosis & diagnosis code relevant to this request:  Dx/Dx Code:							
Does the member have a contraindication to the requested medication?				☐ Yes			
illeuica	ation:			□ No			
<b>Requests for all non-preferred medications</b> : Does the methave a history of trial and failure of or contraindication or into the preferred COPD agents? <i>Refer to</i> <a href="https://papdl.com/prdrug-list">https://papdl.com/prdrug-list</a> for a list of preferred and non-preferred medications class.			itolerance <u>referred-</u>	□ Yes	Medication Taken Previously (start and date and dose):	end 	
	If requesting for daily quantity exceeding daily limit (Refer to <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx</a> ), please provide supporting information:						
Therapeutic Duplication:  If concurrently prescribed a therapeutic duplicate (i.e. another drug in the same class or dose different from the agent being requested):  □ For an inhaled glucocorticoid, is being titrated to or tapered from another inhaled glucocorticoid □ For an inhaled long-acting anticholinergic, is being titrated to or tapered from another inhaled long-acting anticholinergic □ For an inhaled long-acting beta-agonist, is being titrated to or tapered from another inhaled long-acting beta-agonist □ Has a medical reason for concomitant use of the requested medications that is supported by peer-reviewed literature or national treatment guidelines-supporting evidence:							
SUBM	IT MEDICAL RECORD INFORMATI			<u>тем.</u>			
INITIAL REQUEST FOR DALIRESP:  ☐ Member has severe COPD according to the current GOLD guidelines							
	Member has severe COPD based on medical history, physical exam findings and lung function tests (forced expiratory						
	ears ther causes of chronic airflow limitations have been excluded, such as asthma, bronchiectasis, heart failure, ıberculosis, etc						
<ul> <li>Member has experienced more than 2 COPD exacerbations per year that required an ED visit, hospitalizatio of oral steroids despite 1 of the following:</li> </ul>						se	

		For members with an eosinophil count ≥ 100cells/microliter, maximum therapeutic doses of or intolera contraindication to regular scheduled use of ALL of the following:	nce or					
		☐ Inhaled long-acting beta 2 agonist (LABA):						
		☐ Inhaled long-acting anticholinergic/muscarinic antagonist (LAMA):						
		☐ Inhaled corticosteroid:						
		For members with an eosinophil count < 100cells/microliter, maximum therapeutic doses of or intolera contraindication to regular scheduled use of ALL of the following:     Inhaled long-acting beta 2 agonist (LABA):	nce or					
		☐ Inhaled long-acting anticholinergic/muscarinic antagonist (LAMA):						
П	Does r	not have suicidal ideation						
		per has a history of suicide attempt(s), bipolar disorder, major depressive disorder, schizophrenia, substai	nce					
		disorder(s), anxiety disorder(s), borderline personality disorder, and/or antisocial personality disorder						
		Was evaluated and treated for above mental health condition(s) by a psychiatrist						
		Psychiatrist has determined the member is a candidate for treatment with Daliresp						
		mber does not have a history of the above mental health conditions						
		Prescriber performed a mental health evaluation						
RENEW	AL RE	EQUIEST FOR DALIRESP:						
	Frequ	ency of COPD exacerbations has decreased since starting Daliresp (number of exacerbations in last						
	-	·						
	Does r	not have suicidal ideations						
	Was e	evaluated for new onset or worsening symptoms of anxiety or depression						
		treatment with Daliresp						
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION:								
		clinical information to support the request on nedical necessity must be submitted.  Provider Signature:  Date:						
Dla a sessa a s		rtmont will reground via fay or phone within 24 hours						

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)